Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s12879-021-06221-5 http://scihub22266oqcxt.onion/10.1186/s12879-021-06221-5 34058989!8165348!34058989     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       BMC+Infect+Dis 2021 ; 21 (1): 506 Nephropedia Template TP {{tp|p=34058989|t=2021. Effects of early corticosteroid use in patients with severe coronavirus disease 2019 |pdf=|usr=}}{{34058989}} gab.com Text Effects of early corticosteroid use in patients with severe coronavirus disease 2019 JO: BMC Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=34058989 #FOAvip BACKGROUND: Coronavirus disease 2019 (COVID-19) is associated with acute respiratory distress syndrome, and corticosteroids have been considered as possible therapeutic agents for this disease. However, there is limited literature on the appropriate timing of corticosteroid administration to obtain the best possible patient outcomes. METHODS: This was a retrospective cohort study including patients with severe COVID-19 who received corticosteroid treatment from March 2 to June 30, 2020 in seven tertiary hospitals in South Korea. We analyzed the patient demographics, characteristics, and clinical outcomes according to the timing of steroid use. Twenty-two patients with severe COVID-19 were enrolled, and they were all treated with corticosteroids. RESULTS: Of the 22 patients who received corticosteroids, 12 patients (55%) were treated within 10 days from diagnosis. There was no significant difference in the baseline characteristics. The initial PaO(2)/FiO(2) ratio was 168.75. The overall case fatality rate was 25%. The mean time from diagnosis to steroid use was 4.08 days and the treatment duration was 14 days in the early use group, while those in the late use group were 12.80 days and 18.50 days, respectively. The PaO(2)/FiO(2) ratio, C-reactive protein level, and cycle threshold value improved over time in both groups. In the early use group, the time from onset of symptoms to discharge (32.4 days vs. 60.0 days, P = 0.030), time from diagnosis to discharge (27.8 days vs. 57.4 days, P = 0.024), and hospital stay (26.0 days vs. 53.9 days, P = 0.033) were shortened. CONCLUSIONS: Among patients with severe COVID-19, early use of corticosteroids showed favorable clinical outcomes which were related to a reduction in the length of hospital stay. Twit Text FOAVip Effects of early corticosteroid use in patients with severe coronavirus disease 2019 ????BMC Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=34058989 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34058989 #FOAvip English Wikipedia <ref>{{Cite pmid|34058989}}</ref> Effects of early corticosteroid use in patients with severe coronavirus disease 2019 #MMPMID34058989 Hyun JH; Kim MH; Sohn Y; Cho Y; Baek YJ; Kim JH; Ahn JY; Choi JY; Yeom JS; Ahn MY; Kim EJ; Baek JH; Kim YK; Choi H; Jeong SJ BMC Infect Dis 2021[May]; 21 (1): 506 PMID34058989show ga BACKGROUND: Coronavirus disease 2019 (COVID-19) is associated with acute respiratory distress syndrome, and corticosteroids have been considered as possible therapeutic agents for this disease. However, there is limited literature on the appropriate timing of corticosteroid administration to obtain the best possible patient outcomes. METHODS: This was a retrospective cohort study including patients with severe COVID-19 who received corticosteroid treatment from March 2 to June 30, 2020 in seven tertiary hospitals in South Korea. We analyzed the patient demographics, characteristics, and clinical outcomes according to the timing of steroid use. Twenty-two patients with severe COVID-19 were enrolled, and they were all treated with corticosteroids. RESULTS: Of the 22 patients who received corticosteroids, 12 patients (55%) were treated within 10 days from diagnosis. There was no significant difference in the baseline characteristics. The initial PaO(2)/FiO(2) ratio was 168.75. The overall case fatality rate was 25%. The mean time from diagnosis to steroid use was 4.08 days and the treatment duration was 14 days in the early use group, while those in the late use group were 12.80 days and 18.50 days, respectively. The PaO(2)/FiO(2) ratio, C-reactive protein level, and cycle threshold value improved over time in both groups. In the early use group, the time from onset of symptoms to discharge (32.4 days vs. 60.0 days, P = 0.030), time from diagnosis to discharge (27.8 days vs. 57.4 days, P = 0.024), and hospital stay (26.0 days vs. 53.9 days, P = 0.033) were shortened. CONCLUSIONS: Among patients with severe COVID-19, early use of corticosteroids showed favorable clinical outcomes which were related to a reduction in the length of hospital stay. |*COVID-19 Drug Treatment[MESH] |Adrenal Cortex Hormones/*therapeutic use[MESH] |Aged[MESH] |COVID-19/diagnosis[MESH] |Female[MESH] |Humans[MESH] |Length of Stay[MESH] |Male[MESH] |Middle Aged[MESH] |Republic of Korea[MESH] |Respiratory Distress Syndrome[MESH]Effects of early corticosteroid use in patients with severe coronaviru(epmc).pdf DeepDyve Pubget Overpricing